149998-17-4

Basic information

• Product Name: 2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE
• Synonyms: 2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE;2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE（WS205051）
• CAS NO: 149998-17-4
• Molecular Formula: C₆H₆Br₂N₂*ClH
• Molecular Weight: 302.39
• Mol File: 149998-17-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 203-204 °C (decomp)
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE(149998-17-4)
• EPA Substance Registry System: 2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE(149998-17-4)

Safety Data

• Hazardous Substances Data: 149998-17-4(Hazardous Substances Data)

Usage

General Description

2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE is a chemical compound with the molecular formula C12H11Br2N2.HCl. It is an organic compound that is commonly used as a reagent in organic synthesis and pharmaceutical research. 2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE is known for its ability to react with various functional groups, making it a valuable tool in the development of new chemical compounds. Additionally, 2,4-DIBROMOPHENYLHYDRAZINE HYDROCHLORIDE has been studied for its potential pharmacological properties and has shown promise in the treatment of certain diseases and disorders. However, it is important to handle this compound with caution, as it can be harmful if not handled properly.

Upstream product

• 615-57-6 2,4-dibromo-aniline 

Downstream Products

• 156941-60-5 7-bromotryptamine hydrochloride 

Relevant articles and documents

Discovery, structure-activity relationship studies, and anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists

The μ-opioid receptor (MOR) is the major opioid receptor targeted by most analgesics in clinical use. However, the use of all known MOR agonists is associated with severe adverse effects. We reported that the 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-ones are novel opioid receptor agonists. Subsequent structural modification resulted in the potent MOR/KOR (κ-opioid receptor) agonists 19, 20, and 21. Testing the analgesic effect of these in WT B6 mice (tail-flick test) gave ED50 values of 8.4, 10.9, and 26.6 mg/kg, respectively. The 1-phenyl-3,6,6-trimethyl-1,5,6,7- tetrahydro-4H-indazol-4-one core could be addressed in 1 or 2 synthetic steps with moderate to high percent of yield. In the adenylyl cyclase assay, compound 19 displayed a MOR/KOR agonist profile, with IC50 values of 0.73 and 0.41 μM, respectively. Current results suggest that compound 19 is a promising lead to go further development and in vitro/in vivo adverse effects studies.

INTERMEDIATES TO TETRAHYDRO-BETA-CARBOLINES

3-Ethanamine and 3-ethanamine related compounds are provided that are useful intermediates and have beneficial central nervous system activity.

Tetrahydro-β-carbolines

The present invention provides tetrahydro-betacarboline compounds having useful central nervous system activity.